Search filters

List of works by Kathryn Packman

Abstract 2179: Antitumor activity of JNJ-63576253 (TRC253), a small molecule antagonist of F877L mutant and wild-type androgen receptor

scholarly article

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer ⬇️

scientific article published on December 16, 2011

Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model

scientific article published on July 2007

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines ⬇️

scientific article published on August 3, 2012

Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment

scientific article published on 01 June 2020

Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy

scientific article

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

scientific article

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

scientific article

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

scientific article

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity

scientific article published on November 2006

Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors

scientific article

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

scientific article

Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability

scientific article published on 3 September 2013

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097 ⬇️

scientific article published on January 21, 2011

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation ⬇️

scientific article published on June 24, 2011

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

scientific article published on November 2006

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

scientific article

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models ⬇️

scientific article published on February 11, 2013

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

scientific article published on 3 May 2011

Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.

scientific article

Preclinical evaluation of the novel multi-targeted agent R1530.

scientific article published on 8 May 2011

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T

scientific article published in August 2006

Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models

scientific article published on 6 January 2010

Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach

scientific article published on 8 May 2014

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties

scientific article published on 22 September 2009

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

scientific article published on 15 June 2010

RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response

scientific article published on 23 August 2013

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

scientific article published on April 2016

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation ⬇️

scientific article published on December 28, 2011

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

scholarly article

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

scientific article published on 01 September 2020

The Impact of the Bone Marrow Microenvironment on T Cell Redirection Therapeutics ⬇️

scholarly article

Paulina is supported by:

About Paulina

Help